Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Neuroimaging in human MDMA (Ecstasy) users.

Cowan RL, Roberts DM, Joers JM.

Ann N Y Acad Sci. 2008 Oct;1139:291-8. doi: 10.1196/annals.1432.007.

2.

Neuroimaging research in human MDMA users: a review.

Cowan RL.

Psychopharmacology (Berl). 2007 Jan;189(4):539-56. Epub 2006 Jul 18. Review.

PMID:
16847678
3.

Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy').

Ricaurte GA, McCann UD, Szabo Z, Scheffel U.

Toxicol Lett. 2000 Mar 15;112-113:143-6. Review.

PMID:
10720723
4.

(+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals.

Ricaurte GA, Yuan J, McCann UD.

Neuropsychobiology. 2000;42(1):5-10. Review.

PMID:
10867550
5.

Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects.

Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ.

J Psychopharmacol. 2006 Mar;20(2):164-75. Review.

PMID:
16510475
6.

(+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies.

McCann UD, Eligulashvili V, Ricaurte GA.

Neuropsychobiology. 2000;42(1):11-6. Review.

PMID:
10867551
7.

The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system.

White SR, Obradovic T, Imel KM, Wheaton MJ.

Prog Neurobiol. 1996 Aug;49(5):455-79. Review.

PMID:
8895996
8.

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.

Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.

J Psychopharmacol. 2006 Mar;20(2):211-25. Review.

PMID:
16510479
9.

Neuropharmacology and neurotoxicity of 3,4-methylenedioxymethamphetamine.

Gudelsky GA, Yamamoto BK.

Methods Mol Med. 2003;79:55-73. Review.

PMID:
12506690
10.
11.

The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI.

Pharmacol Rev. 2003 Sep;55(3):463-508. Epub 2003 Jul 17. Review.

12.

The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.

Gouzoulis-Mayfrank E, Daumann J.

J Psychopharmacol. 2006 Mar;20(2):188-93. Review.

PMID:
16510477
13.

How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?

Kish SJ.

Pharmacol Biochem Behav. 2002 Apr;71(4):845-55. Review.

PMID:
11888575
14.

3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.

Baumann MH, Wang X, Rothman RB.

Psychopharmacology (Berl). 2007 Jan;189(4):407-24. Epub 2006 Mar 16. Review.

15.

Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

Green AR, Cross AJ, Goodwin GM.

Psychopharmacology (Berl). 1995 Jun;119(3):247-60. Review.

PMID:
7675958
17.

Effects of (+/-) 3,4-methylenedioxymethamphetamine (MDMA) on sleep and circadian rhythms.

McCann UD, Ricaurte GA.

ScientificWorldJournal. 2007 Nov 2;7:231-8. Review.

18.

3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans.

Steele TD, McCann UD, Ricaurte GA.

Addiction. 1994 May;89(5):539-51. Review.

PMID:
7913850
19.

3,4-methylenedioxymethamphetamine (MDMA): current perspectives.

Meyer JS.

Subst Abuse Rehabil. 2013 Nov 21;4:83-99. doi: 10.2147/SAR.S37258. eCollection 2013. Review.

20.
Items per page

Supplemental Content

Write to the Help Desk